Many studies have demonstrated that endogenous TGF-β1 contributes to EMT through the TGFβ signaling pathway, which indicates that the inhibition of the TGF-β1 signaling pathway may be an effective cancer treatment. This evidence concerns the gene TGFB1 and cancer.